Ionis Pharmaceuticals (IONS) Tops Q3 EPS by 39c; Offers F22 Revenue Guidance

Ionis Pharmaceuticals (NASDAQ: IONS) reported Q3 EPS of ($0.33), $0.39 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $160 million versus the consensus estimate of $145.75 million.

GUIDANCE:

Ionis Pharmaceuticals sees FY2022 revenue of $575 million, versus the consensus of $595 million.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Creatd files Form S-1 and reports Q1 2026 financial results
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI